Rezdiffra Signals New Beginnings for NASH Drug Development

agregó una foto Other

2025-07-09 09:59:05

The therapeutic landscape for non-alcoholic steatohepatitis (NASH) has undergone a dramatic transformation with Madrigal Pharmaceuticals' introduction of Rezdiffra (resmetirom), marking an unprecedented milestone in hepatic medicine. This revolutionary medication stands as the inaugural FDA-approved treatment specifically targeting NASH with fibrosis, fundamentally changing how clinicians...

0 Commentarios 0 Acciones 108 Views 0 Vista previa